Answers are grounded in this paper and cite their sources.
Population-based study shows reduced all-cause mortality in pacemaker recipients using SGLT2 inhibitors, suggesting better outcomes.
SGLT2i therapy was associated with reduced risk of all-cause mortality and HF-related hospitalizations following pacemaker implantation. Future randomized studies are needed to confirm this association.
No takes yet. Share an insight, caveat, or question.
Avidan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: